University of Utah | United States
Author Profile
Scopus
EARLY ACADEMIC PURSUITS
Bijina Balakrishnan embarked on her academic journey in the field of biotechnology with a Bachelor of Science degree in Biology & Chemistry from the University of Calicut, Kerala, India, in 1999. She further pursued her passion for biotechnology by obtaining a Master of Science degree in Biotechnology from Cochin University of Science and Technology, Kerala, India, in 2002. Her dedication to advancing knowledge in the field led her to pursue a Doctor of Philosophy (PhD) in Biotechnology, which she successfully completed at Cochin University of Science and Technology, Kerala, India, in 2008.
PROFESSIONAL ENDEAVORS
Balakrishnan's professional journey has been characterized by a steadfast commitment to research excellence and innovation. She has held various significant positions in esteemed academic and research institutions, including:
RESEARCH SCIENTIST University of Utah, Salt Lake City (2021 - Present)
RESEARCH ASSOCIATE University of Utah, Salt Lake City (2019 - 2021)
POST-DOCTORAL FELLOW University of Utah, Salt Lake City (2014 - 2019)
POST-DOCTORAL FELLOW Nanyang Technological University, Singapore (2008)
SENIOR RESEARCH FELLOW Kannur University, India (2007 - 2008)
GRADUATE RESEARCHER Cochin University of Science and Technology, India (2003 - 2007)
Balakrishnan's contributions to the field of biotechnology are multifaceted and impactful, spanning from basic research to translational applications. Her research endeavors have primarily focused on rare metabolic disorders, with a particular emphasis on Galactosemia and dilated cardiomyopathy. Some notable contributions include:
- Development and optimization of preclinical therapeutic interventions for Galactosemia and dilated cardiomyopathy.
- Characterization of mouse models for Galactosemia and elucidation of disease mechanisms.
- Design and execution of gene therapy strategies for cardiac-specific conditions.
- Profiling small molecule modulators for novel therapeutic targets.
- Investigation of cellular responses to viral proteins, such as the SARS-CoV-2 Spike protein, and evaluation of potential therapeutic interventions.
IMPACT AND INFLUENCE
Balakrishnan's work has made a significant impact on both the scientific community and the broader field of biotechnology. Her research findings have been presented at numerous conferences and workshops, contributing to the dissemination of knowledge and fostering collaboration among scientists. Additionally, her efforts have led to the development of novel therapeutic approaches for rare metabolic disorders, offering hope to patients and clinicians alike.
ACADEMIC CITATIONS
Balakrishnan's research contributions have been recognized through academic honors and awards, including the Best Researcher Award at the International Research Awards on Cardiology and Cardiovascular Medicine. Moreover, she has received prestigious grants and funding support from organizations such as the Galactosemia Foundation and the National Institutes of Health (NIH).
LEGACY AND FUTURE CONTRIBUTIONS
Balakrishnan's legacy in the field of biotechnology is characterized by her dedication to scientific inquiry, innovation, and translational research. As she continues her professional journey, she remains committed to advancing knowledge, developing novel therapeutic interventions, and mentoring the next generation of scientists. Her future contributions are poised to further shape the landscape of biotechnology and positively impact the lives of individuals affected by rare metabolic disorders.
NOTABLE PUBLICATIONS
Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia 2020(38)
Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors 2021(3)
AAV-based gene therapy prevents and halts the progression of dilated cardiomyopathy in a mouse model of phosphoglucomutase 1 deficiency (PGM1-CDG) 2023(3)
AAV9-based PMM2 gene replacement augments PMM2 expression and improves glycosylation in primary fibroblasts of patients with phosphomannomutase 2 deficiency (PMM2-CDG)
Whole-body galactose oxidation as a robust functional assay to assess the efficacy of gene-based therapies in a mouse model of Galactosemia